Clinical Trials & Research

Food producers can use a mathematical model developed at the National Food Institute, Technical University of Denmark, to ensure their products do not cause botulism. It is the most comprehensive model of its kind. For years, food producers who make lightly preserved, ready-to-eat food have had to follow a set of guidelines to stop growth

Primary endpoint of non-inferior immunogenicity versus the Phase 3 study adult comparator group was met No cases of COVID-19 observed after two doses of vaccine using the primary case definition, consistent with a vaccine efficacy of 100% Safety and tolerability generally consistent with Phase 3 COVE study in adults; no significant safety concerns identified Company

In a new paper, scientists from La Jolla Institute for Immunology (LJI) bring together research findings from COVID-19 researchers around the world. The results are striking: human T cells can target more than 1,400 sites on the SARS-CoV-2 virus. “Our lab and many others have shown this very broad and diverse T cell response,” says

At one year, improvements in fatigue were sustained among those treated with mirikizumab Three separate analyses of real-world data highlight the burden of fatigue and rectal urgency among people living with ulcerative colitis or Crohn’s disease INDIANAPOLIS, May 22, 2021 /PRNewswire/ — In a pre-specified analysis of the Phase 2 SERENITY study, Eli Lilly and

COVID-19 vaccines are the most effective way to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. For people who are already infected, new research suggests the small molecule stimulator of interferon genes (STING) agonist-1, diABZI, may be effective in controlling SARS-CoV-2 infection — including those caused by variants. Led by Sara Cherry from the

May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated data from the Phase 1 CHRYSALIS study showing treatment with amivantamab in combination with lazertinib led to a median duration of response (DOR) of 9.6 months in chemotherapy-naïve patients with non-small cell lung cancer (NSCLC) and epidermal growth factor

Sanford Burnham Prebys has joined doctors and scientists across America at National Cancer Institute (NCI)-designated cancer centers and other organizations to issue a joint statement urging the nation’s physicians, parents and young adults to get the human papillomavirus (HPV) vaccination back on track. Dramatic drops in annual well visits and immunizations during the COVID-19 pandemic

Individuals are often prescribed increasing numbers of medications as they age, and while many of these prescriptions are justifiable, some may be inappropriate. A recent analysis published in the British Journal of Clinical Pharmacology examined the results of all studies investigating associations between potentially inappropriate prescribing–which includes prescribing medications that may not produce benefits relative

 Mavacamten, a potential first-in-class cardiac myosin inhibitor for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), showed improvement in health status compared to placebo at 30 weeks in EXPLORER-HCM trial Findings of new analysis published simultaneously in The Lancet PRINCETON, N.J.–(BUSINESS WIRE) May 15, 2021 — Bristol Myers Squibb (NYSE: BMY) today announced a new analysis of

May 17 2021 An innovative cardiac rehabilitation intervention started earlier and more custom-tailored to the individual improved physical function, frailty, quality-of-life, and depression in hospitalized heart failure patients, compared to traditional rehabilitation programs. Supported by the National Institute on Aging (NIA), part of the National institutes of Health, these new study results were published May

GAITHERSBURG, Md., May 10, 2021 /PRNewswire/ – Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced data from a preclinical study of the company’s combination quadrivalent seasonal flu vaccine (NanoFlu™) and COVID-19 vaccine candidate (NVX-CoV2373). The NanoFlu/NVX-CoV2373 combination vaccine demonstrated positive immune responses to both influenza and SARS-CoV-2. A pre-print of the

University of Alberta scientists have identified a receptor in cells that could be key to preventing permanent hearing loss in childhood cancer survivors who are being treated with the drug cisplatin. The researchers believe by inhibiting the receptor, they may be able to eliminate toxic side-effects from the drug that cause the hearing loss. Cisplatin

INO-4800 was shown to be safe, well-tolerated and immunogenic in all age groups Phase 2 results informed INOVIO’s selection of 2.0 mg dose for the Phase 3 segment of the trial Data published as a preprint in MedRxiv PLYMOUTH MEETING, Pa., May 10, 2021 /PRNewswire/ — INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to

A leading South Australian immunologist has been awarded $3 million from the Federal Government to accelerate work on a locally developed Covid-19 vaccine, in what’s anticipated to be the second line of defence against the virus. Professor John Hayball is a researcher at the University of South Australia and Chief Scientific Officer at Adelaide biotechnology

May 10, 2021 — Today, the U.S. Food and Drug Administration expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to include adolescents 12 through 15 years of age. The FDA amended the EUA originally issued

A team of scientists from the Washington University School of Medicine and the University of Texas Medical Branch, USA, has recently evaluated the durability and robustness of an adenovirus-vectored, spike-based intranasal coronavirus disease 2019 (COVID-19) vaccine in mice. Their analyses reveal that a single dose of the vaccine is capable of inducing both neutralizing and

TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS WIRE) May 08, 2021 –New data from Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s datopotamab deruxtecan (Dato-DXd), a TROP2 directed DXd antibody drug conjugate (ADC), showed preliminary response and disease control in patients with metastatic triple negative breast cancer (TNBC) with disease progression following standard treatment.

Countries like the UK, Israel, and the USA are now in the thick of successful vaccine campaigns against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 pandemic. As the vaccine rollout continues, there have been thousands of anecdotal reports of receivers suffering symptoms of mild fatigue, achiness, and fever in

PREVENT-19 clinical trial expanded to assess the efficacy, safety and immunogenicity of NVX-CoV2373 for the prevention of COVID-19 in up to 3,000 12-17-year-old adolescents President of Research and Development, Gregory Glenn, M.D., to provide update regarding the additional trial arm during World Vaccine Congress GAITHERSBURG, Md., May 3, 2021 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX),

It is now widely known that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), spreads via respiratory droplets. The persistence of the aerosol in the environment largely determines the success of the viral transmission. In addition, the virus-laden droplets can also deposit on various surfaces

Publication of initial primary analysis highlights NVX-CoV2373 cross-protection against B.1.351 variant prevalent in South Africa during study GAITHERSBURG, Md., May 5, 2021 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the publication of results from the initial primary analysis of a Phase 2b clinical trial

Black patients from disadvantaged neighborhoods were significantly more likely to die within five years of surviving a heart attack compared with Black heart attack patients from wealthier neighborhoods and white patients of any socioeconomic means who survive a heart attack, according to a study being presented at the American College of Cardiology’s 70th Annual Scientific

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 30, 2021– Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the World Health Organization (WHO) has issued Emergency Use Listing (EUL) for its COVID-19 vaccine to prevent COVID-19 in individuals 18 years of age and older. “We thank the WHO for their data review and for their issuance of

Last summer, Global Plasma Solutions wanted to test whether the company’s air-purifying devices could kill covid-19 virus particles but could find only a lab using a chamber the size of a shoebox for its trials. In the company-funded study, the virus was blasted with 27,000 ions per cubic centimeter. In September, the company’s founder incidentally

CARMIEL, Israel and BOSTON, April 28, 2021 /PRNewswire/ – Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), today announced that they received

Changi General Hospital (CGH) and the Singapore University of Technology and Design (SUTD) have developed the Blood WArning Technology with Continuous Haemoglobin (BWATCH) sensor, a lightweight monitoring device placed over a patient’s bandage that detects real-time bleeding from wound sites following invasive medical procedures. BWATCH was tested and validated in an observational clinical trial involving

CAMBRIDGE, Mass., April 28, 2021 /PRNewswire/ – Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the New England Journal of Medicine (NEJM) has published the results of the global Phase 3 clinical program of vadadustat for the treatment of anemia due to chronic kidney disease

A team of scientists from A-Alpha Bio., USA, has recently conducted a large-scale screening of 33 therapeutic antibodies to examine their binding affinity to a number of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The team analyzed the impact of potential mutations in the spike receptor-binding domain (RBD) on antibody efficacy. The study is